特纳综合征临床诊疗管理的现状思考

顾威; 赵雪

doi:10.7499/j.issn.1008-8830.2407176

PDF(627 KB)

HTML

中国当代儿科杂志 ›› 2024, Vol. 26 ›› Issue (11) : 1135-1140. DOI: 10.7499/j.issn.1008-8830.2407176

系列述评——生长障碍疾病诊疗

特纳综合征临床诊疗管理的现状思考

顾威, 赵雪

作者信息 +

Reflections on the clinical diagnosis and management of Turner syndrome

GU Wei, ZHAO Xue

Author information +

文章历史 +

摘要

特纳综合征（Turner syndrome, TS）的临床诊断存在延迟，尤其对于嵌合核型患者，诊断延迟将阻碍与年龄相适应的相关治疗，导致不良的健康结局。因此，有必要基于临床现状探索早期诊断和治疗方案的改善措施。此外，随着研究深入，TS的临床诊治重点逐渐扩展至心血管、生育力、过渡期等多方面，以提高患者的预后和生存质量。该文探讨了TS诊疗的临床现状和管理要点，旨在为改善TS诊疗管理提供思考。

Abstract

There is a delay in the clinical diagnosis of Turner syndrome (TS), particularly for patients with mosaic karyotypes. This diagnostic delay can hinder age-appropriate treatments and lead to adverse health outcomes. Therefore, it is necessary to explore improvement measures for early diagnosis and treatment plans based on the current clinical situation. Furthermore, as research progresses, the focus of clinical diagnosis and treatment of TS is gradually expanding to multiple aspects, including cardiovascular health, fertility, and transitional care, in order to improve the prognosis and quality of life of the patients. This paper discusses the current clinical status and management key points of TS diagnosis and treatment, aiming to provide insights for improving the management of TS.

导出引用

顾威, 赵雪. 特纳综合征临床诊疗管理的现状思考[J]. 中国当代儿科杂志. 2024, 26(11): 1135-1140 https://doi.org/10.7499/j.issn.1008-8830.2407176

GU Wei, ZHAO Xue. Reflections on the clinical diagnosis and management of Turner syndrome[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(11): 1135-1140 https://doi.org/10.7499/j.issn.1008-8830.2407176

参考文献

1 中国人体健康科技促进会生育力保护与保存专业委员会. 特纳综合征中国专家共识（2022年版）[J]. 中国实用妇科与产科杂志, 2022, 38(4): 424-433. DOI: 10.19538/j.fk2022040111.
2 Gravholt CH, Viuff M, Just J, et al. The changing face of Turner syndrome[J]. Endocr Rev, 2023, 44(1): 33-69. PMID: 35695701. DOI: 10.1210/endrev/bnac016.
3 Al Alwan I, M K, Amir 1st, et al. Turner syndrome genotype and phenotype and their effect on presenting features and timing of diagnosis[J]. Int J Health Sci (Qassim), 2014, 8(2): 195-202. PMID: 25246887. PMCID: PMC4166992. DOI: 10.12816/0006086.
4 Gravholt CH, Andersen NH, Christin-Maitre S, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome[J]. Eur J Endocrinol, 2024, 190(6): G53-G151. PMID: 38748847. DOI: 10.1093/ejendo/lvae050.
5 Altalib A, AlSulmi E, Bokhari D, et al. Mosaic Turner syndrome with multiple spontaneous pregnancies: a case report[J]. Cureus, 2024, 16(1): e53351. PMID: 38304667. PMCID: PMC10831321. DOI: 10.7759/cureus.53351.
6 Swauger S, Backeljauw P, Hornung L, et al. Age at and indication for diagnosis of Turner syndrome in the pediatric population[J]. Am J Med Genet A, 2021, 185(11): 3411-3417. PMID: 34390317. DOI: 10.1002/ajmg.a.62459.
7 Porcu E, Cipriani L, Damiano G. Reproductive health in Turner's syndrome: from puberty to pregnancy[J]. Front Endocrinol (Lausanne), 2023, 14: 1269009. PMID: 38116311. PMCID: PMC10728473. DOI: 10.3389/fendo.2023.1269009.
8 Fiot E, Alauze B, Donadille B, et al. Turner syndrome: French national diagnosis and care protocol (NDCP; National Diagnosis and Care Protocol)[J]. Orphanet J Rare Dis, 2022, 17(Suppl 1): 261. PMID: 35821070. PMCID: PMC9277788. DOI: 10.1186/s13023-022-02423-5.
9 Wiechec M, Knafel A, Nocun A, et al. What are the most common first-trimester ultrasound findings in cases of Turner syndrome?[J]. J Matern Fetal Neonatal Med, 2017, 30(13): 1632-1636. PMID: 27491505. DOI: 10.1080/14767058.2016.1220525.
10 Bedei I, Gloning KP, Joyeux L, et al. Turner syndrome-omphalocele association: incidence, karyotype, phenotype and fetal outcome[J]. Prenat Diagn, 2023, 43(2): 183-191. PMID: 36600414. DOI: 10.1002/pd.6302.
11 Gao X, Sun Y, Wang J, et al. Predicting the risk of Turner syndrome based on ultrasonographic markers in the first trimester of pregnancy[J]. Chin Med J (Engl), 2023, 136(15): 1879-1881. PMID: 37247621. PMCID: PMC10406061. DOI: 10.1097/CM9.0000000000002622.
12 Mousavi S, Amiri B, Beigi S, et al. The value of a simple method to decrease diagnostic errors in Turner syndrome: a case report[J]. J Med Case Rep, 2021, 15(1): 79. PMID: 33596986. PMCID: PMC7890814. DOI: 10.1186/s13256-021-02673-0.
13 Al ADK, ?ükür NM, ?zturan EK, et al. Body proportions in patients with Turner syndrome on growth hormone treatment[J]. Turk J Med Sci, 2023, 53(2): 518-525. PMID: 37476877. PMCID: PMC10388058. DOI: 10.55730/1300-0144.5612.
14 Lim D, Hassani S, Lupton K, et al. Prevalence, risk factors and management strategies for otological problems in girls with Turner syndrome[J]. Acta Paediatr, 2020, 109(10): 2075-2083. PMID: 31811789. DOI: 10.1111/apa.15128.
15 Eckhauser A, South ST, Meyers L, et al. Turner syndrome in girls presenting with coarctation of the aorta[J]. J Pediatr, 2015, 167(5): 1062-1066. PMID: 26323199. DOI: 10.1016/j.jpeds.2015.08.002.
16 Szybiak W, Kujawa B, Miedziaszczyk M, et al. Effect of growth hormone and estrogen replacement therapy on bone mineral density in women with Turner syndrome: a meta-analysis and systematic review[J]. Pharmaceuticals (Basel), 2023, 16(9): 1320. PMID: 37765128. PMCID: PMC10536543. DOI: 10.3390/ph16091320.
17 Backeljauw P, Blair JC, Ferran JM, et al. Early GH treatment is effective and well tolerated in children with Turner syndrome: NordiNet? IOS and answer program[J]. J Clin Endocrinol Metab, 2023, 108(10): 2653-2665. PMID: 36947589. PMCID: PMC10505549. DOI: 10.1210/clinem/dgad159.
18 Dantas NCB, Braz AF, Malaquias A, et al. Adult height in 299 patients with Turner syndrome with or without growth hormone therapy: results and literature review[J]. Horm Res Paediatr, 2021, 94(1/2): 63-70. PMID: 34134112. DOI: 10.1159/000516869.
19 Gao X, Chen J, Cao B, et al. Correction: first clinical study on long-acting growth hormone therapy in children with Turner sydrome[J]. Horm Metab Res, 2022, 54(6): e5. PMID: 36638815. PMCID: PMC9839421. DOI: 10.1055/a-2008-2304.
20 Roy R, Hazra A, Ghosh S. An observational study on response to growth hormone therapy in Indian patients of short stature with special emphasis on biochemical parameters and bone biomarkers[J]. Indian J Endocrinol Metab, 2023, 27(3): 260-269. PMID: 37583404. PMCID: PMC10424109. DOI: 10.4103/ijem.ijem_303_22.
21 Mondal S, Gargari P, Nagendra L, et al. Growth hormone therapy is associated with improved uterine dimensions in girls with Turner syndrome prior to oestrogen replacement[J]. Clin Endocrinol (Oxf), 2024, 100(1): 66-75. PMID: 37555570. DOI: 10.1111/cen.14957.
22 Isojima T, Yokoya S. Growth in girls with Turner syndrome[J]. Front Endocrinol (Lausanne), 2023, 13: 1068128. PMID: 36714599. PMCID: PMC9877326. DOI: 10.3389/fendo.2022.1068128.
23 Quigley CA, Fechner PY, Geffner ME, et al. Prevention of growth failure in Turner syndrome: long-term results of early growth hormone treatment in the "toddler turner" cohort[J]. Horm Res Paediatr, 2021, 94(1/2): 18-35. PMID: 34111870. DOI: 10.1159/000513788.
24 Aversa T, Li Pomi A, Pepe G, et al. Growth hormone treatment to final height in Turner syndrome: systematic review[J]. Clin Ther, 2024, 46(2): 146-153. PMID: 38151406. DOI: 10.1016/j.clinthera.2023.12.004.
25 Linglart A, Cabrol S, Berlier P, et al. Growth hormone treatment before the age of 4 years prevents short stature in young girls with Turner syndrome[J]. Eur J Endocrinol, 2011, 164(6): 891-897. PMID: 21398400. DOI: 10.1530/EJE-10-1048.
26 中华医学会儿科学分会内分泌遗传代谢学组, 《中华儿科杂志》编辑委员会. Turner综合征儿科诊疗共识[J]. 中华儿科杂志, 2018, 56(6): 406-413. PMID: 29886602. DOI: 10.3760/cma.j.issn.0578-1310.2018.06.002.
27 Kristr?m B, Ankarberg-Lindgren C, Barren?s ML, et al. Normalization of puberty and adult height in girls with Turner syndrome: results of the Swedish Growth Hormone trials initiating transition into adulthood[J]. Front Endocrinol (Lausanne), 2023, 14: 1197897. PMID: 37529614. PMCID: PMC10389045. DOI: 10.3389/fendo.2023.1197897.
28 Kasprzyk J, W?odarczyk M, Sobolewska-W?odarczyk A, et al. Karyotype abnormalities in the X chromosome predict response to the growth hormone therapy in Turner syndrome[J]. J Clin Med, 2021, 10(21): 5076. PMID: 34768596. PMCID: PMC8584940. DOI: 10.3390/jcm10215076.
29 Hasegawa Y, Hasegawa T, Satoh M, et al. Pubertal induction in Turner syndrome without gonadal function: a possibility of earlier, lower-dose estrogen therapy[J]. Front Endocrinol (Lausanne), 2023, 14: 1051695. PMID: 37056677. PMCID: PMC10088859. DOI: 10.3389/fendo.2023.1051695.
30 Donaldson M, Kristr?m B, Ankarberg-Lindgren C, et al. Optimal pubertal induction in girls with Turner syndrome using either oral or transdermal estradiol: a proposed modern strategy[J]. Horm Res Paediatr, 2019, 91(3): 153-163. PMID: 31167218. DOI: 10.1159/000500050.
31 Hasegawa Y, Itonaga T, Ikegawa K, et al. Ultra-low-dose estrogen therapy for female hypogonadism[J]. Clin Pediatr Endocrinol, 2020, 29(2): 49-53. PMID: 32313372. PMCID: PMC7160460. DOI: 10.1297/cpe.29.49.
32 中华医学会内分泌学分会性腺学组. 特纳综合征诊治专家共识[J]. 中华内分泌代谢杂志, 2018, 34(3): 181-186. DOI: 10.3760/cma.j.issn.1000-6699.2018.03.001.
33 阮祥燕, 杜娟, 卢丹, 等. 中国冻存卵巢组织自体移植后首例活产报道[J]. 中国临床医生杂志, 2021, 49(10): 1258-1260. DOI: 10.3969/j.issn.2095-8552.2021.10.037.
34 van der Coelen S, van der Velden J, Nadesapillai S, et al. Navigating fertility dilemmas across the lifespan in girls with Turner syndrome: a scoping review[J]. Hum Reprod Update, 2024, 30(4): 383-409. PMID: 38452347. PMCID: PMC11215162. DOI: 10.1093/humupd/dmae005.
35 Fuchs MM, Attenhofer Jost C, Babovic-Vuksanovic D, et al. Long-term outcomes in patients with Turner syndrome: a 68-year follow-up[J]. J Am Heart Assoc, 2019, 8(11): e011501. PMID: 31131660. PMCID: PMC6585378. DOI: 10.1161/JAHA.118.011501.
36 Chou YY, Wang CJ, Lin CH, et al. Association between cardiovascular anomalies and karyotypes in Turner syndrome patients in Taiwan: a local cohort study[J]. Pediatr Neonatol, 2020, 61(2): 188-194. PMID: 31672476. DOI: 10.1016/j.pedneo.2019.10.001.
37 Birjiniuk A, Weisman AG, Laternser C, et al. Cardiovascular manifestations of Turner syndrome: phenotypic differences between karyotype subtypes[J]. Pediatr Cardiol, 2024, 45(7): 1407-1414. PMID: 37147524. DOI: 10.1007/s00246-023-03159-0.
38 Calanchini M, Bradley-Watson J, McMillan F, et al. Risk assessment for aortic dissection in Turner syndrome: the role of the aortic growth rate[J]. Clin Endocrinol (Oxf), 2024, 100(3): 269-276. PMID: 38214123. DOI: 10.1111/cen.15017.
39 Thunstr?m S, Thunstr?m E, Naessén S, et al. Aortic size predicts aortic dissection in Turner syndrome: a 25-year prospective cohort study[J]. Int J Cardiol, 2023, 373: 47-54. PMID: 36410543. DOI: 10.1016/j.ijcard.2022.11.023.
40 Meccanici F, de Bruijn JWC, Dommisse JS, et al. Prevalence and development of aortic dilation and dissection in women with Turner syndrome: a systematic review and meta-analysis[J]. Expert Rev Cardiovasc Ther, 2023, 21(2): 133-144. PMID: 36688313. DOI: 10.1080/14779072.2023.2172403.
41 Silberbach M, Roos-Hesselink JW, Andersen NH, et al. Cardiovascular health in Turner syndrome: a scientific statement from the American Heart Association[J]. Circ Genom Precis Med, 2018, 11(10): e000048. PMID: 30354301. DOI: 10.1161/HCG.0000000000000048.